Why animal studies cannot suitably assess nanomedicines

Pharmaceutical Technology Europe

Volumn 22, Issue 1, 2010, Pages 38-42

  Bhogal, Nirmala ^a   Seabra, Rita ^a  

^a RUSSELL AND BURCH HOUSE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; BONE CEMENT; DOXORUBICIN; FEDIREX; LIPOSOME; NANOPARTICLE; OSTIM; PACLITAXEL; RAPAMYCIN; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG STABILITY; HEALTH HAZARD; HUMAN; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; REVIEW; TRANSDERMAL DRUG ADMINISTRATION;

EID: 74949096870     PISSN: 01646826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. M.C. Roco and W. Sims Bainbridge (Eds.) Societal implications of nanoscience and nanotechnology (Kluwer Academic, The Netherlands, 2001) pp 370.
2. V. Wagner, Nat. Biotechnol., 24(10), 1211-1217 (2006).
3. M.J. Alonso, Biomedicine & Pharmacotherapy, 58(3), 168-172 (2004).
4. The Project on Emerging Nanotechnologies, Inventories (2009). www.nanotechproject.com
5. Scientific Committee on Emerging and Newly Identified Health Risks, Opinion on the appropriateness of the risk assessment methodology in accordance with the technical guidance documents for new and existing substances for assessing the risks of nanomaterials (2007). http://ec.europa.eu
6. K.M. Kadish (Ed.), Fullerenes: Recent Advances in the chemistry and Physics of Fullerenes and Related Materials (Electrochemical Society, 1997) pp 332-340.
7. Environmental Toxicity Council (ETC) Group, occasional paper series, 7(1) (2003). www.etcgroup.org
8. The Council Of The European Communities, Council Directive 93/42/EEC (1993). http://eur-lex.europa.eu
9. FDA, A Report of the U.S. Food and Drug Administration Nanotechnology Task Force (July 2007). www.fda.gov
10. Organisation for Economic Co-operation and Development, Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, Pesticies and Biotechnology (July, 2009). www.oecd.org
11. G. Oberdörster et al., Particle Fibre and Toxicology, 2(7) (2005).
12. W.I. Hagens et al., Regul. Toxicol. Pharmacol., 49(3), 217-229 (2007).
13. A.E. Nel et al., Nat. Mater., 8(7), 543-557 (2009).
14. V. Labhesetwar et al., J. Pharm. Sci., 87(10), 1229-1234 (2000).
15. L. Lacerda et al., Adv. Drug Deliv. Rev., 58(14), 1460-1470 (2006).
16. A. Nel et al., Science, 311(5761), 622-627 (2006).
17. J.A Matriano et al., Pharm. Res., 19(1), 63-70 (2002).
18. L. Wang et al., J. Immunol., 180, 4722-4727 (2008).
19. B. Godin and E. Touitou, Adv. Drug Deliv. Rev., 59(11), 1152-1161 (2007).
20. J. caussin et al., Biochim. Biophys. Acta., 1778(6), 1472-1482 (2008).
21. J. Stahl et al., Eur. J. Pharmac. Biopharmac., 72(2), 310-316 (2009).
22. C. Giese et al., Artif. Organs, 30(10), 803-808 (2006).
23. D. Gaucher et al., J. Exp. Med., 205(13), 3119-3131 (2008).
24. S.T. Stern and S.E. McNeil, Toxicol. Sci., 101(1), 4-21 (2008).
25. N. Kobayashi et al., Toxicology, 264(1-2), 110-118 (2009).
26. K. BéruBé et al., Altern. Lab. Anim: ATLA, 37, 89-141 (2009).
27. G. Oberdörster et al., J. Nanosci. Nanotechnol., 29(8), 4996-5007 (2009).
28. T. Ogiso et al., J. Drug Target., 9(1), 49-59 (2001).
29. H. Harashima, Pharm. Res., 13(7), 1049-1054 (1996).
30. C. Gretzer et al., J. Biomater. Sci. Polym. Ed., 17(6), 669-687 (2006).
31. S. Souliman, Eur. J. Pharm. Sci., 27(1), 72-79 (2006).